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ABSTRACT: The damage inflicted on our society by mental health and substance use issues is reaching epidemic proportions with few signs
of abating. One new and innovative strategy for addressing these comorbid issues has been the development of outdoor behavioral healthcare
(OBH). This study compared the effectiveness of three post-acute adolescent substance use situations: OBH, treatment as usual (TAU), and
no structured treatment (NST). The simulated target population was 13-17 years old with comorbid substance use and mental health issues.
When costs were adjusted for actual completion rates of 94% in OBH, 37% in TAU, and $0 for NST, the actual treatment costs per person were
$27 426 for OBH and $31 113 for TAU. OBH also had a cost–benefit ratio of 60.4% higher than TAU, an increased Quality in Life Years (QALY)
life span, societal benefits of an additional $36 100, and 424% better treatment outcomes as measured by the Youth Outcome Questionnaire
(YOQ) research instrument.
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The damage inflicted on the United States population by mental health and substance use issues is reaching epidemic proportions with few signs of abating. When compared to other
countries, the U.S. possesses the highest death rate from mental health and substance abuse disorders (12 deaths per 1 00 000
individuals, almost twice as much as the second leading country).1 Mental health issues are the leading cause of disease burden in the United States for females and the third leading
cause for males, and the disease burden from drug use disorders
is four times higher in the U.S. than in comparable countries.1
The U.S. suicide rate has grown by 18% since 2006,2 with drug
use linked to higher likelihood of suicidal thoughts and
behavior.3
Substance use during adolescence lies at the very confluence
of worsening trends in mental health care.4 Adolescence is
associated with multiple processes that compound a client’s
vulnerability that include, but are not limited to: identity formation, greater responsibilities, the influence of peer relations
in decision making, and the emergence of more complex thinking. Developmental factors underpinning impulsivity also contribute to the negative synergistic relationship between
substance use disorder (SUD) and mental health problems.5
Mental, emotional, and behavioral disorders among youth
cost the nation $247 billion yearly due to crime, health services,
and lost productivity.6 Although youth are not necessarily
involved in the labor market, their disorders can impact families and other related systems in ways that have rippling economic costs—and costs that do not “readily translate to dollars
and cents.”6 Many of these costly disorders begin to present
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early in life, suggesting efforts to interdict should be stressed at
adolescence.7
Resolution of SUD and mental health comorbidity requires
sophisticated and integrated approaches. Current interventions
targeting comorbid diagnoses are often undermined by the frustrating and substantial likelihood of relapse.4 The difficulty of
achieving positive clinical outcomes (ie, mental health gains
along with sobriety) makes evaluation of interventions more difficult. There are, however, best practices emerging from a growing body of literature. Such practices usually include
comprehensive, multimodal interventions that are integrated
into a single treatment program. These programs begin with
assessment and followed by attendance, treatment completion,
and medication compliance throughout an intensive period of
care coordinated by a single practitioner.4,7
Another reason for treatment difficulties when trying to
address these complex conditions with adolescents is their ineffectiveness when conducted through didactic mediums (e.g.,
listening while sitting in a chair). Adolescents experiencing serious
psychological distress are seeing or speaking less often with a mental health professional.8 And even when help is sought, 13% of
mental health discharges and 10% of substance use discharges are
readmitted to U.S. hospitals within 30 days.8 The need to solidify
effective treatment programs, as well as investigate new intervention strategies, merits the reexamination of current behavioral
healthcare treatment. This is especially true in the areas of evidence-based programing, effective treatments, and best practices.
One new and innovative strategy for addressing these needs
has been the development of outdoor behavioral healthcare
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(OBH). OBH is an important and rapidly growing clinical
approach to behavioral healthcare for adolescents. OBH therapists not only deliver the same therapeutic elements often
implemented in traditional “office therapies,” but supplement
these approaches with the benefits typically found in other
healthy ecosystems that create an exponentially richer therapeutic environments. OBH consists of:
– Extended backcountry travel and wilderness living
experiences long enough to allow for clinical assessment,
establishment of treatment goals, and a reasonable course of
treatment not to exceed the productive impact of the experience,
– Active and direct use of clients’ participation and responsibility in their therapeutic process,
– Continual group living and regular formal group therapy sessions to foster teamwork and social interactions,
– Individual therapy sessions, often supported by the
inclusion of family therapy,
– Adventure experiences utilized to appropriately enhance
treatment by fostering the development of eustress (ie, the
positive use of stress) as a beneficial element in the therapeutic experience,
– The use of nature in reality as well as a metaphor within
the therapeutic process, and
– A strong ethic of care and support throughout the therapeutic experience.9
OBH outcome-based research has produced promising
results over the past 5 years. In one study, 36 Australian adolescent outpatients with substance abuse and comorbid mental
health issues completed a 70-day manualized wilderness
adventure therapy program. Statistically signiﬁcant gains
(P = .026) in psychological resilience and social self-esteem
were found at discharge and 3 months post-discharge. For participants in clinical ranges prior to the program, there were
large and positive effect size changes in depressive symptomology (g = −0.80; 37% change) as well as with behavioral and
emotional functioning (g = −0.70; 33% change). All of these
changes were retained at 3 months following discharge.10
Bettman et al11 conducted a meta-analysis on the clinical
effectiveness of wilderness therapy for private pay clients in
North America. Search processes resulted in a meta-analysis
based on 36 studies, totaling 2399 participants receiving OBH.
The meta-analyses found medium effect sizes for all six constructs assessed: self-esteem (g = 0.49), locus of control
(g = 0.55), behavioral observations (g = 0.75), personal effectiveness (g = 0.46), clinical measures (g = 0.50) and interpersonal
measures (g = 0.54).11 These findings include greater resilience
in the face of substance use.

DeMille et al12 examined the longitudinal impact of OBH
on comorbid adolescents. Findings showed that comorbid adolescents who attended an Outdoor Behavioral Healthcare
treatment program were functioning significantly better than
the comparison group 1 year following the program as measured by the YOQ 2.01.13 Comorbid adolescents who remained
in their communities were still at acute levels of psychosocial
dysfunction during the same time span. A regression analysis
revealed age, race, and gender not to be significant predictors of
improvement.
Lewis14 reinforced these findings, demonstrating significant
gains in relieving symptoms related to SUDs and enhancing
clients’ quality of life. And most importantly, clients maintained these significant beneficial changes >1 year
post-discharge.
The purpose of this study was to evaluate the effectiveness
of three post-acute behavioral health strategies for treating
adolescents with substance use and mental illness comorbid
issues. This study compared the differences between these
treatment programs on their cost, completion rates, healthcare,
and societal outcomes. It specifically focused its research on the
cost-effectiveness analysis on OBH, TAU, and no structured
treatment (NST) application to comorbid behavioral healthcare issues. The research protocol received full review, protection, and approval of the Institutional Review Board (IRB) of
the University of New Hampshire.15

Methods
Outcomes considered
Cost-effectiveness is the balance of expenses related to successful
treatment. Cost-effectiveness analyses are widely accepted
methods of economic evaluation comparing monetary costs
with nonmonetary outcomes (eg, increased quality of life,
improved clinical functioning).16,17 The research methodology
used for the cost-effectiveness analysis followed the guidelines
outlined by the Second Panel on Cost-effectiveness in Health
and Medicine18 and the updated recommendations for this
Panel’s report.19 Care was taken to follow cost-effectiveness
guidelines, using standard methodological practices to improve
comparability and quality, and to include analysis from both a
healthcare and societal sector perspective. The healthcare sector included medical costs reimbursed by third-party payers as
well as paid out-of-pocket by patients.
Treatment completion rate is the full completion of the designated treatment program. This is one of the strongest predictors of successful therapy.20,21 Clients who complete substance
abuse treatment are “more likely to remain abstinent, have
fewer relapses, higher level of employment and higher wages,
fewer readmissions, less future criminal involvement, and better health” (p. 130).22 As further outlined by the National
Institute on Drug Abuse (NIDA) (2018): “. . .the biggest
drawback to therapeutic communities is the large percentage of
enrollees (⩾75%) who never complete treatment” (p. 1).22

Gass et al.
Clinical healthcare outcomes measure the effectiveness of
behavioral healthcare by focusing on who needs treatment,
how they access treatment, what treatment works best in those
settings, and how to keep people engaged in treatment long
enough to benefit clients.2 For example, clients who remain in
treatment for longer periods of time are more likely to achieve
maximum benefits.7 Specifically, treatment episodes for
⩾3 months is often a predictor of successful outcomes.16
Societal outcomes hold great importance in the treatment of
substance abuse. For example, substance abuse treatment is
associated with reductions in crime rates, reduced incarceration, public safety benefits, positive transition from criminal
justice system to the community, and is more cost effective
than prison or other punitive measure.23 The societal sector
also included expenses related to medical care, infectious
issues, pre and postnatal care, mental disorders, government
and private transfer payments, and other programs (eg,
unemployment benefits, welfare payments, disability
benefits).23-25

Post-Acute Care Treatment Programs
Outdoor behavioral healthcare. OBH can be defined as a 24-hour
intermediate outdoor group living environment that includes
group, individual, and family therapy. These therapies are
designed to address behavioral and emotional issues by utilizing treatment modalities centered on nature, challenging experiences combined with reflection/mindfulness, interpersonal
development, and intrapersonal growth.
Treatment as usual. There are a number of choices for treatment with mental health and substance abuse issues. As identified in the Treatment Episode Data Set2 the most commonly
accessible options for treatment service or state jurisdiction for
substance use or mental health issues were: outpatient (39%),
detoxification (21%), intensive outpatient (13%), short-term
residential (10%), long-term residential (8%), hospital residential (>1%). The percentages associated with each category represent the percentage of discharges that occurred in the United
States in 2016.2
No structured treatment. This implies no systematic postacute treatment (ie, only acute episodic care is involved), and
with estimated rates of visits to an emergency room (ER), inpatient stays, and rates of premature death.25

Participants
The cost–benefit analysis was assessed based on treating a simulated group of 13 to 17-year-old comorbid adolescent substance users (eg, ICD10, alcohol, F10.20; marijuana, F11.20, or
opioid, F12.20) also presenting a comorbid clinical diagnosis
(ICD 10) of at least one of the following: depression (F32.2),
anxiety (F41.1), or suicidal ideation (Z91.5, Z91.89). After
admission and evaluation at emergency services, clients were
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discharged to an adolescent hospital-based inpatient psychiatric unit before TAU or OBH (the cost of the precipitating utilization events is not included in the study).
Consequences of the program were based on estimates of
health care utilization, health status, and quality-adjusted life
years compared to expected rates in NST, completed treatment,
and partial treatment. Valeck’s26 research was used to simulate
the number of individuals admitted to a treatment program and
the number of individuals requiring treatment in emergency
rooms and inpatient stays for the NST group.27 These numbers
were based on 130 people who abused or were dependent [on
opioids], 32 of this group (24.6%) required “emergency department visits for misuse or abuse,” 10 (7.7%) were admitted into
“inpatient admissions for abuse,” and one who died (0.8%).
Such simulations are critical in the development of cost–benefit
and cost-effectiveness in the behavioral healthcare field.28
Using the level of care required to treat the identified clients, program costs for both OBH and TAU were determined
through surveys conducted with 18 OBH programs and 11
TAU programs. NST were assumed to be zero for these
analyses.
Program benefits were based on three different scenarios:
(1) Short-term utilization benefit: These were determined
from estimated ER rates for emergency and intensive
inpatient use for substance abusers with the assumption
that expected utilization for NST would not be experienced by those completing 100% of the course of postacute treatment. The median cost of emergency room29
and inpatient services was used and adjusted for medical
inflation.30
(2) Health benefits: Based on the findings from DeMille
et al,12 2.75 was indexed for OBH, 1.0 for TAU, and 0.0
for NST. Cost–benefit was indexed to TAU where the
cost of TAU was expected to bring a benefit of 1.0; and
the program cost of OBH would be indexed to the same
value. Thus, if the cost of OBH was the same as TAU, the
benefit would be equal to 2.75; if the cost of OBH was
less than TAU, but benefit would be >2.75; conversely if
the cost of OBH was greater than TAU, the benefit
would be <2.75.12
(3) Long-term utilization (based on premature death estimates): This was based on estimates of the number of
deaths in the NST substance abuse population where
100% completion of either program would result in these
values being zero.2 This figure was used to estimate the
years of life lost31 and the economic value of each year of
life lost32 adjusted for medical inflation.

Cost Factors
The average per diem charge and length of treatment for OBH
was determined by a random selection of 10 OBH Council
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Table 1. Treatment costs for 90 days, completions rates, and multipliers.
Program
type

Treatment
completion rate

Multiplier for treatment
costs and benefit

Insurance pay (80% of
allowed charges)

NST

0%

0.00

$0.00

OBH

100%

1.00

$28 274

94.00%

⩾75% to <100

0.88

$24 726

1.50%

⩾50% to <75%

0.63

$17 671

1.50%

⩾25 to <50%

0.38

$10 603

1.50%

0 to <25%

0.13

$3 534

1.50%

100%

1.00

$45 360

37.20%

⩾75% to <100

0.88

$39 667

15.70%

⩾50% to <75%

0.63

$28 350

15.70%

⩾25 to <50%

0.38

$17 010

15.70%

TAU

Treatment completion
rates used in models

0.00%

Table 2. Benchmark: expectation of NST.
Category

ER visit*

IP stay**

Premature death

QALY (years lost)

Societal issues (annual)#

Expected rate per 100

25

8

0.77

41.7

NA

Value (insurance paid rate)

$959

$6 158

$67 537

NA

$948

Value per 100

$23 971

$49 262

NA

$2 166 377

$94 757

*Median insurance pay.
**Median insurance pay: $1338.64 per day @ 4.6 days.
#Worker productivity + criminal justice issues.

(OBHC) members from the membership records in the
Winter of 2019.33 The median per diem cost for these OBH
members on November 1, 2018 was $561 per day with the
average length of treatment being 90 days.34
The average per diem charge and length of treatment for
TAU was determined from the random selection of 10 TAU
programs from the National Association for Therapeutic
Schools and Programs Membership Handbook who were not
also OBHC members in the Winter of 2019. The median per
diem charge for TAU on November 1, 2018 was $900 with
the average length of treatment stay set at 90 days to match
the same length of time used for OBH (note the minimum
level or dosage of effective treatment has been identified by
SAMHSA, 2018 to be 90 days for substance use treatment).2
In order to determine the societal benefits from OBH and
TAU, two non–health care-related issues were used to assign
the annual costs associated with SUD ($74.2 billion in 2013
dollars). Twenty-six percent of this cost was due to a loss of
worker productivity and 9.7% due to criminal justice.35 The
total cost burden associated with these two non–health carerelated issues were adjusted to 2018 dollars and calculated on a
per person cost.

Results

Table 1 presents the combined factors of program costs for one
person as well as 100, program completion rates. As one can
see, the program costs for OBH were approximately $17 000
less for each than TAU programing costs.
Table 2 summarizes the cost burden shouldered by Society
when a person falls into the category of “no structured treatment.” Some of the expenses needing to be covered by this segment of our society include ER visits, inpatient delivery of
services, premature death occurrences, losses in Quality in Life
Years (QALY) and societal factors (eg, worker productivity,
criminal justice issues)
Table 3 examines what occurs when all of costs and benefits are combined together, both when program completion
is simulated for 100% (Table 3A) and when the actual program completion rates are applied for OBH and TAU (Table
3B). In the simulated cohort of 100 individuals, the short
and QALY benefits were the same. But because the costs
were lower, the short-term cost–benefit of OBH was 60%
more, the value of reduced premature death was 60% more
as were other societal benefits (eg, worker productivity,
criminal justice issues), and the value of greater treatment

Gass et al.
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Table 3A. CBA healthcare utilization and premature deaths: Comparing OBH, TAU, and NST in adolescents assuming 100% completion rates in
OBH & TAU.
Program
completion
rates

Program type

Program costs per 100

Health care utilization

Premature deaths

Total pay per
person

Total pay per 100

Benefits

CBA

Benefits

CBA

0.0%

NST

$0.00

$0

$0.00

0.0000

$0.00

0.0000

100.0%

OBH (90 days)

$28 274.40

$2 827 440

$73 232.83

0.0259

$5 195 150

1.8374

100.0%

TAU (90 days)

$45 360.00

$4 536 000

$73 232.83

0.0161

$5 195 150

1.1453

Delta (OBH-TAU)

−$17 086

−$1 708 560

$0

0.0098

$0.00

0.6921

Percent difference
(to TAU)

−37.67%

−37.67%

0.00%

60.43%

0.00%

60.43%

Table 3B. CBA, YOQ, and Societal benefits: Comparing OBH, TAU, and NST in adolescents assuming 100% completion rates in OBH & TAU.
Program
completion
rates

Program type

Program
pay per 100

Youth Outcome Questionnaire (YOQ)

Societal benefits
(work-based
productivity,
criminal justice)

Indexed program
costs (to TAU) per 100

Indexed YOQ
impact per 100

CBA

Benefits in 1 CBA
year

0%

NST

0

0.00

0.00

0.0000

$0.00

0.000

100%

OBH (90 days)

$2 827 440

76.59

275.00

3.5906

$94 757

0.034

100%

TAU (90 days)

$4 536 000

100.00

100.00

1.0000

$94 757

0.021

Delta (OBH-TAU)

−$1 708 560

−23.41

175.00

2.5906

$0.00

0.013

Percent difference
(to TAU)

−37.67%

−23.41%

175.00%

259.06%

0.00%

60.43%

benefit was 259% better in OBH. The cost of treatment was
higher in OBH and TAU than the short-term benefit of
reduced ER and IP, but this is the case with many health
interventions.
Table 4A shows results adjusted for empirically derived
completion rates for the outcomes of utilization and QALYs
(based on expected deaths). Assuming a cohort of 100 individuals combined with each program’s completion rate (94%
for OBH, and 37% for TAU), the cost and benefits (ie, utilization) were calculated based on multipliers in Table 1. In this
situation, the price of OBH was 12% less than TAU, the shortterm utilization and QALY benefits were 41% better, shortterm CBA of OBH was 60% better, the value of reduced
premature death was 6% more.
Table 4B shows results adjusted for empirically derived
completion rates for the outcomes of utilization and QALYs
(based on expected deaths). Assuming a cohort of 100 individuals combined with each program’s completion rate (94%
for OBH, and 37% for TAU), the cost and benefits (ie, utilization) were calculated based on multipliers in Table 1. In this
situation, the value of YOQ benefits were 362% better and

the combined value of issues related to worker productivity
and criminal justice issues was 60% better in OBH compared
to TAU.

Discussion

OBH is less expensive than TAU when patients are 100%
successful in completing treatment; and it is also less expensive if the completion rate is based upon empirical rates
found in the literature (ie, 94% for OBH, 37% for TAU). A
90-day treatment for both OBH and TAU was used for calculations—the recommended minimum by SAMSHA for
SUD treatment. Given its higher rate of completion, this
study shows OBH is more cost effective post-acute care
treatment regimen for SUD than TAU with regard to shortterm utilization, health improvement, longevity, and general
societal benefits of improved worker productivity and criminal justice issues.
It is important to note this comparison only used 1 year cost
for utilization and societal benefits; and it is a very defensible
assumption that these benefits are cumulative, and the actual
dollars saved will improve year after year.
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Table 4A. CBA healthcare utilization and premature deaths: Comparative effectiveness of OBH, TAU, and NST in adolescents using treatment
completion rates in OBH & TAU.
Program
completion
rates

Program type

Program costs per 100

Utilization

0.0%
94.0%

Total pay per
person

Total pay
per 100

Benefits

CBA

Benefits

CBA

NST

$0.00

$0.00

$0.00

NA

$0.00

NA

OBH (90 days)

$28,274

$2 657 794

$68 839

0.02590

$4 883 441

1.84

1.5%

$24 726

$37 089

$961

0.02590

$68 147

1.84

1.5%

$17 671

$26 507

$687

0.02590

$48 705

1.84

1.5%

$10 603

$15 904

$412

0.02590

$29 223

1.84

1.5%

$3 534

$5 301

$137

0.02590

$9 741

1.84

SUM

$27 426

$2 742 596

$71 035

0.02590

$5 039 256

1.84

$45 360

$1 687 392

$27 243

0.01614

$1 932 596

1.15

15.7%

$39 667

$622 777

$10 055

0.01614

$713 276

1.15

15.7%

$28 350

$445 095

$7 186

0.01614

$509 774

1.15

15.7%

$17 010

$267 057

$4 312

0.01614

$305 864

1.15

15.7%

$5 670

$89 019

$1 437

0.01614

$101 955

1.15

SUM

$31 113

$3 111 340

$50 232

0.01614

$3 563 465

1.15

Delta (OBH-TAU)

−$3 687

−$368 744

$20 803

0.00976

$1 475 791

0.69

Percent difference (to TAU)

−11.85%

−11.85%

41.41%

60.43%

41.41%

37.2%

TAU (90 days)

The findings of this study clearly demonstrate the greater
outcomes of OBH for post-acute adolescents to both TAU
and NST, and at a reduced program cost compared to TAU.
One of the questions clearly becomes which clients should be
considered for OBH and which clients should be considered
for TAU. If insurance companies increase their coverage of
these SUD post-acute care treatment systems, it is essential to
understand if the criteria for entry into both programs are
identical. Or does OBH—the more novel program—require
additional rules of admission. The general requirements for
standard therapy for post-acute substance abuse therapy have
been outlined above and guidelines for TAU is well described
and documented.14
One of the strengths of OBH programing with immediate
post-acute clients is its ability to address clients at different
stages of change, most notably the precontemplation state of
change.34 Precontemplation is a state where clients often deny
any need to change. At this stage, clients project externalizing
blaming behaviors, a lack of ownership for the problems, and no
motivation to change. What OBH does effectively in producing
client change is guide a client behavior from this stage to a state
of contemplation.36 At this stage, clients obtain a new awareness
of their problems, own their responsibility for the problem, and
consider healthy change to address their therapeutic issue. A
healthy change process from this adaptation emerges that transforms clients’ perspectives in the primary phase of treatment.37

QALY (based on
expected deaths)

60.43%

For some individuals this may not be enough treatment to assist
them in completing their transformation to lasting healthy
change. In such cases the secondary programing for change is
necessary beyond the first 90 days of treatment. Thus, the entry
criteria for both OBH and TAU is identical, even for those who
are resistant to change at the beginning of therapy.
Two extremely important and well-developed mechanisms
have recently occurred to help insurers as well as clients identify those OBH programs that possess both the clinical and
ethical qualities sought to deliver best practices, evidence-based
research, and effective treatment.
The first mechanism outlines the clinical criteria for OBH
guidelines for children and adolescents.38 Vetted by the
Outdoor Behavioral Healthcare Research Council scientists
(obhrc.org), this document provides clear guidelines which
define medical necessity, examples of services and programs
that generally do not meet the clinical criteria of OBH, the
well-researched factors of safety, effectiveness, quality, and
costs, program requirements and expectations, and criteria for
treatment admission as well as continuation and discharge.38
The second mechanism is an accreditation process for OBH
that delivers 26 years of experience in ongoing development for
the OBH field. Coordinated by the Association for Experiential
Education (AEE), the accreditation program maintains a
strong focus of objectivity and transparency in its 27-step process.39 Many facets are covered by the accreditation process,
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Table 4B. CBA, YOQ, and Societal benefits: Comparative effectiveness of OBH, TAU, and NST in adolescents using reported completion rates in
OBH & TAU.
Program
completion
rates

Program type

Program
pay per 100

Youth Outcome Questionnaire (YOQ)

Societal benefits (workbased productivity,
criminal justice)

Indexed
program costs
(to TAU) per 100

Benefits in 1
year

CBA

$0.00

NA

Indexed YOQ
impact per 100

CBA

0.0%

NST

$0

0.00

0.00

94.0%

OBH (90 days)

$2 657 794

0.62

258.50

4.41

$89 072

0.034

1.5%

$37 089

0.55

3.61

4.41

$1 243

0.034

1.5%

$26 507

0.39

2.58

4.41

$888

0.034

1.5%

$15 904

0.23

1.55

4.41

$533

0.034

1.5%

$5 301

0.08

0.52

4.41

$178

0.034

SUM

$2 742 596

0.60

266.75

4.41

$91 914

0.034

$1 687 392

1.00

37.20

1.00

$35 250

0.021

15.7%

$622 777

0.87

13.73

1.00

$13 010

0.021

15.7%

$445 095

0.62

9.81

1.00

$9 298

0.021

15.7%

$267,057

0.38

5.89

1.00

$5 579

0.021

15.7%

$89 019

0.13

1.96

1.00

$1 860

0.021

SUM

$3 111 340

0.69

57.79

0.84

$64 996

0.021

Delta (OBH-TAU)

−$368 744

−0.081

208.96

3.57

$26 918

0.013

Percent difference
(to TAU)

−11.85%

423.62%

41.41%

60.43%

37.2%

TAU (90 days)

−11.85%

including philosophical, therapeutic, educational, and ethical
principles; program government, management operations,
therapeutic assessment, delivery, oversight and evaluation;
oversight of adventure experiences; staffing, transportation,
equipment, nutrition, and hygiene; the technical aspects of
OBH experiences; supervision of clients, therapist qualifications, and risk management procedures.39

Limitations
The current study builds upon a growing literature showing the
effectiveness of OBH treatment. The study draws upon multiple, yet similar, settings within OBH and TAU treatments in
order to better generalize findings. However, larger samples
and additional varieties of settings regarding both interventions would strengthen the generalizability of the findings. In
addition, one large question not in this study that merits close
scrutiny is the question of dosage for OBH programing (as
well as TAU), not addressed in the current study. Certainly
research should seek to discern just how many days are needed
to achieve the level of significant clinical differences caused by
OBH programing. Such is also the case for several levels of
TAU (eg, residential treatment). While the average OBH programing days in the study was 90 days, the range of OBH

361.56%

NA

treatment days was 1-327 days of treatment. This certainly will
be crucial in the decision by reimbursers and insurance payers
in their efforts to make the most beneficial, yet economical,
decisions for clients.
The preceding comparison of the completion rates, relative
costs, effectiveness, and benefits of OBH and TAU demonstrates
the potential benefit of insurance coverage of all types of postacute SUD treatment, especially OBH. However, further inquiry
is needed to substantiate and elaborate upon these initial findings.
Future directions in the movement toward insurance coverage of
post-acute SUD treatment should further address additional economic evaluation of OBH and TAU, implications of insurance
coverage for OBH and TAU, the significance of the Affordable
Care Act and growing payment of services by the public sector,
and thoughts on more direct involvement in SAMHSA’s specialized mental health treatment approaches programs.
Note that relapse figures for the three groups involved in the
study were not included in the calculations. Future studies on
relapse from OBH programing are certainly important to
study in the near future.

Conclusion

Professionals can use the information provided in this article on
research outcomes, cost-effectiveness, and treatment completion
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rates for decision making. As the new era of behavioral health
parity begins, effectiveness studies such as this one should help
stakeholders improve decision making processes. For example,
insurance providers could use these three factors to determine
the most effective treatment at the lowest cost. Healthcare advocates and families would apply their findings to increase these
successes in attaining proper insurance reimbursement for a
family’s expenditures. State insurance commissioners could use
these factors to advocate for appropriate coverage for consumers
in need of post-acute SUD care in their state. Behavioral healthcare programing that targets post-acute SUD care would apply
these factors to increase their client base.
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